{"id":53339,"date":"2023-09-20T09:45:17","date_gmt":"2023-09-20T09:45:17","guid":{"rendered":"https:\/\/medsname.com\/lenalid\/"},"modified":"2026-04-30T16:30:28","modified_gmt":"2026-04-30T16:30:28","slug":"lenalid","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/lenalid\/","title":{"rendered":"Lenalid"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Lenalid<\/strong> \u2014 Lenalidomide 5\/10\/25 mg (Natco Pharma). Immunomodulatory drug (IMiD) for multiple myeloma (newly diagnosed and relapsed\/refractory), 5q-myelodysplastic syndrome, and mantle cell lymphoma. Modern IMiD with greater potency and fewer neuropathy\/sedation side effects than thalidomide.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>\u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/li>\n<li>\u03a3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03cc \u03c6\u03ac\u03ba\u03b5\u03bb\u03bf \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/li>\n<li>\u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/li>\n<li>\u0391\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 (<a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03b4\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>\u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2:<\/strong> \u03b1\u03bd \u03b7 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03bc\u03ad\u03c3\u03b1 \u03c3\u03b5 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03b5\u03c2 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c4\u03b7\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5 \u03c7\u03c9\u03c1\u03af\u03c2 \u03c0\u03c1\u03cc\u03c3\u03b8\u03b5\u03c4\u03bf \u03ba\u03cc\u03c3\u03c4\u03bf\u03c2. <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\">\u0394\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae<\/a>.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>Lenalid ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor \u2014 never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Specialist-supervised cancer therapy<\/strong> \u2014 this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Pregnancy black-box \u2014 strict prevention programme<\/strong><br \/>All IMiDs are severely teratogenic (thalidomide most notoriously \u2014 phocomelia). Mandatory pregnancy-prevention programme (REMS\/iCare equivalent): pregnancy testing before, during, and after; two effective contraceptive methods; counselling for both partners; no blood donation during therapy or for 4 weeks after. Even one dose during pregnancy can cause severe malformations.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>VTE risk \u2014 thromboprophylaxis<\/strong><br \/>IMiDs carry significantly elevated risk of deep vein thrombosis and pulmonary embolism, especially in combination with corticosteroids or doxorubicin. Mandatory thromboprophylaxis: low-dose aspirin (low-risk), or LMWH\/warfarin\/DOAC (higher-risk patients). Specialist-determined.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Myelosuppression + monitoring<\/strong><br \/>All IMiDs cause myelosuppression \u2014 neutropenia, thrombocytopenia, anaemia. Weekly FBC during initiation; monthly maintenance. Renal dose adjustment (lenalidomide especially \u2014 significant renal accumulation).<\/div>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3>When is this used?<\/h3>\n<p>Immunomodulatory drug (IMiD) for multiple myeloma (newly diagnosed and relapsed\/refractory), 5q-myelodysplastic syndrome, and mantle cell lymphoma. Modern IMiD with greater potency and fewer neuropathy\/sedation side effects than thalidomide.<\/p>\n<h3>How is it taken?<\/h3>\n<p>Once daily, typically in cycles (e.g., 21 days on, 7 days off for lenalidomide). Specific dose and schedule are myeloma-protocol-specific (Rd, RVd, KRd, etc.). Specialist-determined by tumour response and tolerability.<\/p>\n<h3>Pregnancy prevention?<\/h3>\n<p>Mandatory programme: monthly pregnancy tests, two effective contraceptive methods, partner contraception, counselling. Even one dose during pregnancy causes severe malformations. No blood donation during therapy or for 4 weeks after stopping.<\/p>\n<h3>Common side effects?<\/h3>\n<p>IMiD class: VTE, fatigue, rash, GI (constipation, diarrhoea), myelosuppression. Lenalidomide: less neuropathy than thalidomide. Pomalidomide: often better tolerated than thalidomide; renal-friendly. Thalidomide: peripheral neuropathy, sedation.<\/p>\n<h3>\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd;<\/h3>\n<p>Anticoagulants \u2014 adjust based on VTE prophylaxis strategy. Digoxin levels may rise. Erythropoietin agents + IMiD \u2014 increased thrombosis risk; use only with mandatory thromboprophylaxis.<\/p>\n<h3>Renal monitoring?<\/h3>\n<p>Lenalidomide: dose-adjust by CrCl (significant renal accumulation). Pomalidomide: less renal effect but still monitor. Thalidomide: renally cleared metabolite \u2014 monitor renal function.<\/p>\n<h3>\u03a4\u03b9 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03b1\u03bd \u03c7\u03ac\u03c3\u03c9 \u03bc\u03b9\u03b1 \u03b4\u03cc\u03c3\u03b7;<\/h3>\n<p>Take when you remember if &lt;12 hours late; otherwise skip and resume \u2014 do not double up. Notify oncology team if multiple doses missed.<\/p>\n<h3>\u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03cc\u03c2;<\/h3>\n<p>Inactivated vaccines OK; live vaccines contraindicated during IMiD therapy. Optimise vaccinations before starting if possible.<\/p>\n<h3>Long-term complications?<\/h3>\n<p>IMiD therapy: secondary primary malignancies (especially with extended use), cumulative VTE risk, neuropathy (thalidomide especially).<\/p>\n<h3>When is treatment stopped?<\/h3>\n<p>Specialist-determined: response duration, toxicity, planned treatment break, transition to maintenance therapy. IMiD maintenance therapy is now standard in myeloma \u2014 typically lenalidomide post-autologous stem cell transplant continued for 2-3 years or until intolerance.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Cancer Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/xeloda\/\">Xeloda<\/a> \u2014 capecitabine 500 mg \u2014 oral 5-FU prodrug for breast\/colorectal\/gastric cancers<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/altraz\/\">Altraz<\/a> \u2014 anastrozole 1 mg \u2014 aromatase inhibitor for post-menopausal breast cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/xbira\/\">Xbira<\/a> \u2014 abiraterone 250 mg \u2014 CYP17 inhibitor for metastatic prostate cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/zoldria\/\">Zoldria<\/a> \u2014 zoledronic acid IV \u2014 for bone metastases and hypercalcaemia<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 for chemotherapy-induced anaemia<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>\u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03c5\u03bd\u03ce\u03bd:<\/strong> Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.<\/div>","protected":false},"excerpt":{"rendered":"<p>Lenalid (Lenalidomide 5\/10\/25 mg) \u2014 Natco IMiD for multiple myeloma. Pregnancy black-box; mandatory thromboprophylaxis with corticosteroid combinations.<\/p>","protected":false},"featured_media":53340,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53339","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/53339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=53339"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/53340"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=53339"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=53339"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=53339"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=53339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}